Abelson murine leukemia virus (Ab-MLV) is a rapidly transforming retrovirus that contains the oncogene v-abl. Expression of this or other oncogenic forms of abl induces transformation of many types cells and stimulates the growth and differentiation of others. In addition, expression of abl can be lethal. All of these effects are mediated by a single product, which in the case of Ab-MLV, is called Abelson protein. This molecule is a member of the non-receptor protein tyrosine kinase family and the protein tyrosine kinase activity is required for any of the effects of Ab-MLV on cell growth. Although the mechanism by which Abelson protein alters cellular growth most certainly involves tyrosine phosphorylation of cellular proteins, very little is known about the actual pathways involved. The experiments proposed here address this issue in five ways. First, we will use genetically engineered and biologically selected viruses to understand the role of particular portions of the protein in the transformation of lymphoid cells in vivo and in vitro and in the lethal response. Second, we will continue our efforts to isolate dominant negative transformation mutants. Third, we will use the most informative mutants identified in the first two parts of the study to understand the way in which the mutations alter Abelson protein function. Fourth, we will build on our recent observation that an active Abelson protein is required for transformed pre-B cells to transit the G1 phase of the cell cycle. Finally, we will use pre-B lymphocytes transformed by conditional mutants of Ab-MLV to understand the relationship between transformation and differentiation in the Ab-MLV system. Together these experiments will help determine the mechanism by which activated ab/ genes alter cellular growth and differentiation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA024220-15
Application #
3166371
Study Section
Virology Study Section (VR)
Project Start
1978-09-01
Project End
1996-03-31
Budget Start
1993-04-01
Budget End
1994-03-31
Support Year
15
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Tufts University
Department
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02111
Yi, Chae-ryun; Rosenberg, Naomi (2008) Mutations affecting the MA portion of the v-Abl protein reveal a conserved role of Gag in Abelson murine leukemia virus (MLV) and Moloney MLV. J Virol 82:5307-15
Yi, Chae-Ryun; Rosenberg, Naomi (2007) Gag influences transformation by Abelson murine leukemia virus and suppresses nuclear localization of the v-Abl protein. J Virol 81:9461-8
Marchlik, Erica; Kalman, Richard; Rosenberg, Naomi (2005) Decreased virus population diversity in p53-null mice infected with weakly oncogenic Abelson virus. J Virol 79:11618-26
Kharas, Michael G; Deane, Jonathan A; Wong, Stephane et al. (2004) Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells. Blood 103:4268-75
Warren, David; Griffin, Deborah S; Mainville, Celine et al. (2003) The extreme carboxyl terminus of v-Abl is required for lymphoid cell transformation by Abelson virus. J Virol 77:4617-25
Unnikrishnan, Indira; Rosenberg, Naomi (2003) Absence of p53 complements defects in Abelson murine leukemia virus signaling. J Virol 77:6208-15
Afar, D E; Han, L; McLaughlin, J et al. (1997) Regulation of the oncogenic activity of BCR-ABL by a tightly bound substrate protein RIN1. Immunity 6:773-82
Parmar, K; Rosenberg, N (1996) Ras complements the carboxyl terminus of v-Abl protein in lymphoid transformation. J Virol 70:1009-15
Raffel, G D; Parmar, K; Rosenberg, N (1996) In vivo association of v-Abl with Shc mediated by a non-phosphotyrosine-dependent SH2 interaction. J Biol Chem 271:4640-5
Wang, L C; Chen, Y Y; Rosenberg, N (1995) Pre-B-cells transformed by ts Abelson virus rearrange kappa and lambda [correction of gamma] genes in early G1. Curr Top Microbiol Immunol 194:355-61

Showing the most recent 10 out of 23 publications